Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Trend over time of HIV-1 drug resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs) and their drivers: A cohort study from Antiviral Response Cohort Analysis (ARCA)

Title: Trend over time of HIV-1 drug resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs) and their drivers: A cohort study from Antiviral Response Cohort Analysis (ARCA)
Authors: Rancan, Ilaria; Cassol, Chiara; Graziani, Lucia; Tilli, Marta; Malcontenti, Costanza; Russo, Chiara; Bottanelli, Martina; Bracchitta, Fiorenza; Papaioannu, Rebecka; Labate, Laura; Mora, Sara; Bezenchek, Antonia; Shallvari, Adrian; Di Biagio, Antonio; Rossetti, Barbara; Pellicanò, Giovanni
Contributors: Rancan, Ilaria; Cassol, Chiara; Graziani, Lucia; Tilli, Marta; Malcontenti, Costanza; Russo, Chiara; Bottanelli, Martina; Bracchitta, Fiorenza; Papaioannu, Rebecka; Labate, Laura; Mora, Sara; Bezenchek, Antonia; Shallvari, Adrian; Di Biagio, Antonio; Rossetti, Barbara; Pellicanò, Giovanni
Publisher Information: WILEY
Publication Year: 2023
Collection: Università degli Studi di Messina: IRIS
Subject Terms: HAART; HIV-1; NNRTI; RAM; antiretroviral therapy; resistance
Description: The rise of HIV-1 drug resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs) threatens the long-term success of NNRTI-based therapies. Our study aims to describe the circulation of major resistance-associated mutations (RAMs) for NNRTIs in people living with HIV (PLWH) in Italy from 2000 to 2020. We included 5982 naives and 28 505 genotypes from 9387 treatment-experienced PLWH from the Antiviral Response Cohort Analysis (ARCA) cohort. Transmitted drug resistance (TDR) was found in 12.5% and declined from 17.3% in 2000-2003 to 10.9% in 2016-2020 (p = 0.003). Predictors of TDR were viral subtype B [vs. non-B, adjusted odds ratio (aOR) = 1.94, p < 0.001], zenith viral load (VL) (per 1 log(10) higher, aOR=0.86, p=0.013), nadir CD4 cell count (per 100 cells/& mu;L increase aOR=0.95, p=0.013). At least one RAM for NNRTIs among treatment experienced PLWH was detected in 33.2% and pre-treatment drug resistance (PDR) declined from 43.4% in 2000-2003 to 20.9% in 2016-2020 (p < 0.001). Predictors of PDR were sexual transmission route (vs. others, aOR=0.78, p < 0.001), time since HIV diagnosis (per 1 month longer, aOR=1.002, p < 0.001), viral subtype B (vs. non B, aOR=1.37, p < 0.001), VL (per 1 log(10) higher, aOR=1.12, p < 0.001), nadir CD4 count (per 100 cells/& mu;L increase, aOR=0.91, p < 0.001), previous exposure to any NNRTI (aOR=2.31, p < 0.001) and a more recent calendar year sequence (any time span > 2008 vs. 2000-2003, any aOR
Document Type: article in journal/newspaper
File Description: STAMPA
Language: English
Relation: info:eu-repo/semantics/altIdentifier/pmid/37439411; info:eu-repo/semantics/altIdentifier/wos/WOS:001026960600001; volume:24; issue:11; firstpage:1150; lastpage:1157; numberofpages:8; journal:HIV MEDICINE; https://hdl.handle.net/11570/3268368
DOI: 10.1111/hiv.13525
Availability: https://hdl.handle.net/11570/3268368; https://doi.org/10.1111/hiv.13525; https://onlinelibrary.wiley.com/doi/10.1111/hiv.13525
Rights: info:eu-repo/semantics/openAccess
Accession Number: edsbas.C063D932
Database: BASE